96 related articles for article (PubMed ID: 31196639)
1. Bile Acids and Portal Hypertension.
Pablo Arab J; Barrera F; Arrese M
Ann Hepatol; 2017 Nov; 16 Suppl 1():S83-S86. PubMed ID: 31196639
[TBL] [Abstract][Full Text] [Related]
2. Bile Acids and Portal Hypertension.
Arab JP; Barrera F; Arrese M
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
[TBL] [Abstract][Full Text] [Related]
3. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
[TBL] [Abstract][Full Text] [Related]
4. Advances in bile acid medicinal chemistry.
Sharma R; Long A; Gilmer JF
Curr Med Chem; 2011; 18(26):4029-52. PubMed ID: 21824088
[TBL] [Abstract][Full Text] [Related]
5. Gut-liver axis signaling in portal hypertension.
Simbrunner B; Mandorfer M; Trauner M; Reiberger T
World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
[TBL] [Abstract][Full Text] [Related]
6. FXR agonist GW4064 improves liver and intestinal pathology and alters bile acid metabolism in rats undergoing small intestinal resection.
Cao Y; Xiao Y; Zhou K; Yan J; Wang P; Yan W; Cai W
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G108-G115. PubMed ID: 30920307
[TBL] [Abstract][Full Text] [Related]
7. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice.
Péan N; Doignon I; Garcin I; Besnard A; Julien B; Liu B; Branchereau S; Spraul A; Guettier C; Humbert L; Schoonjans K; Rainteau D; Tordjmann T
Hepatology; 2013 Oct; 58(4):1451-60. PubMed ID: 23686672
[TBL] [Abstract][Full Text] [Related]
8. The contributions of bacteria metabolites to the development of hepatic encephalopathy.
Gilbert MC; Setayesh T; Wan YY
Liver Res; 2023 Dec; 7(4):296-303. PubMed ID: 38221945
[TBL] [Abstract][Full Text] [Related]
9. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction.
Sauerbruch T; Hennenberg M; Trebicka J; Beuers U
Front Physiol; 2021; 12():718783. PubMed ID: 34393832
[TBL] [Abstract][Full Text] [Related]
10. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
11. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
Watanabe M; Houten SM; Mataki C; Christoffolete MA; Kim BW; Sato H; Messaddeq N; Harney JW; Ezaki O; Kodama T; Schoonjans K; Bianco AC; Auwerx J
Nature; 2006 Jan; 439(7075):484-9. PubMed ID: 16400329
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.
Yusta B; Matthews D; Flock GB; Ussher JR; Lavoie B; Mawe GM; Drucker DJ
Mol Metab; 2017 Jun; 6(6):503-511. PubMed ID: 28580281
[TBL] [Abstract][Full Text] [Related]
13. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.
Pereira-Fantini PM; Lapthorne S; Joyce SA; Dellios NL; Wilson G; Fouhy F; Thomas SL; Scurr M; Hill C; Gahan CG; Cotter PD; Fuller PJ; Hardikar W; Bines JE
J Hepatol; 2014 Nov; 61(5):1115-25. PubMed ID: 24999016
[TBL] [Abstract][Full Text] [Related]
14. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol.
Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340
[TBL] [Abstract][Full Text] [Related]
15. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.
Hu X; Bonde Y; Eggertsen G; Rudling M
J Intern Med; 2014 Jan; 275(1):27-38. PubMed ID: 24118394
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between bile acids and intestinal microbiota in host metabolism and health.
Nie YF; Hu J; Yan XH
J Zhejiang Univ Sci B; 2015 Jun; 16(6):436-46. PubMed ID: 26055905
[TBL] [Abstract][Full Text] [Related]
17. Bile acids induce visceral hypersensitivity via mucosal mast cell-to-nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis.
Li WT; Luo QQ; Wang B; Chen X; Yan XJ; Qiu HY; Chen SL
FASEB J; 2019 Feb; 33(2):2435-2450. PubMed ID: 30260705
[TBL] [Abstract][Full Text] [Related]
18. Bile acids and colon cancer: Is FXR the solution of the conundrum?
Gadaleta RM; Garcia-Irigoyen O; Moschetta A
Mol Aspects Med; 2017 Aug; 56():66-74. PubMed ID: 28400119
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
Halilbasic E; Fuchs C; Traussnigg S; Trauner M
Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721
[TBL] [Abstract][Full Text] [Related]
20. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
